Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Dec 02, 2022 4:01pm EST
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference Nov 23, 2022 8:00am EST
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress Nov 08, 2022 4:01pm EST
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Nov 04, 2022 4:01pm EDT
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 Nov 01, 2022 4:05pm EDT
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 Oct 26, 2022 2:01am EDT
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Oct 14, 2022 7:08am EDT
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Oct 10, 2022 4:01pm EDT
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre Sep 28, 2022 4:01pm EDT
